Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | FS222 |
Synonyms | |
Therapy Description |
FS222 is a tetravalent bispecific antibody that binds to PD-L1 (CD274) and CD137 (4-1BB), which crosslinks cytotoxic T-lymphocytes to PD-L1-expressing tumor cells, potentially resulting in CD137 mediated activation of T-cells (PMID: 32345647). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FS222 | FS-222|FS 222 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 TNFRSF9 Antibody 30 | FS222 is a tetravalent bispecific antibody that binds to PD-L1 (CD274) and CD137 (4-1BB), which crosslinks cytotoxic T-lymphocytes to PD-L1-expressing tumor cells, potentially resulting in CD137 mediated activation of T-cells (PMID: 32345647). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04740424 | Phase I | FS222 | FS222 First in Human Study in Patients With Advanced Malignancies | Recruiting | ESP | 1 |